Harrow Health (HROW) Relaunches TRIESENCE

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Harrow Health (HROW) Relaunches TRIESENCE

Harrow Relaunches TRIESENCE®

October 3, 2024 7:00 AM EDT

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservativefree synthetic corticosteroid that is approved by the U.S. Food and Drug Administration (FDA) for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.

In commenting on the announcement, Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said, We are very excited to have brought TRIESENCE back to the U.S. market, providing ophthalmologists... More